Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2020.03.008 http://scihub22266oqcxt.onion/10.1016/j.drudis.2020.03.008 32348877!7194552!32348877     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Discov+Today 2020 ; 25 (6): 959-964 Nephropedia Template TP {{tp|p=32348877|t=2020. Chemical evolution for taming the pathogenic kinase PAK1 |pdf=|usr=}}{{32348877}} gab.com Text Chemical evolution for taming the pathogenic kinase PAK1 JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32348877 #FOAvip To celebrate the 25th anniversary of the cloning of the first mammalian p21-activated kinases (PAKs) (RAC/CDC42-activated kinases) by Ed Manser, the first international PAK symposium was held in NYC in October 2019. Among six distinct PAKs in mammals, PAK1 is the major 'pathogenic kinase', the abnormal activation of which is responsible for a wide variety of diseases and disorders including cancers, ageing processes and infectious and inflammatory diseases such as pandemic coronaviral infection. Recently, for a clinical application, a few potent (highly cell-permeable and water-soluble) PAK1 blockers have been developed from natural or synthetic PAK1 blockers (triptolide, vitamin D3 and ketorolac) via a series of 'chemical evolutions' that boost pharmacological activities >500 times. Twit Text FOAVip Chemical evolution for taming the pathogenic kinase PAK1 ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32348877 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32348877 #FOAvip English Wikipedia <ref>{{Cite pmid|32348877}}</ref> Chemical evolution for taming the pathogenic kinase PAK1 #MMPMID32348877 Maruta H; Kittaka A Drug Discov Today 2020[Jun]; 25 (6): 959-964 PMID32348877show ga To celebrate the 25th anniversary of the cloning of the first mammalian p21-activated kinases (PAKs) (RAC/CDC42-activated kinases) by Ed Manser, the first international PAK symposium was held in NYC in October 2019. Among six distinct PAKs in mammals, PAK1 is the major 'pathogenic kinase', the abnormal activation of which is responsible for a wide variety of diseases and disorders including cancers, ageing processes and infectious and inflammatory diseases such as pandemic coronaviral infection. Recently, for a clinical application, a few potent (highly cell-permeable and water-soluble) PAK1 blockers have been developed from natural or synthetic PAK1 blockers (triptolide, vitamin D3 and ketorolac) via a series of 'chemical evolutions' that boost pharmacological activities >500 times. |Aging/drug effects/metabolism[MESH] |Animals[MESH] |Enzyme Inhibitors/pharmacology[MESH] |Evolution, Chemical[MESH] |Humans[MESH] |Inflammation/drug therapy/metabolism[MESH] |Mammals/metabolism[MESH] |Neoplasms/drug therapy/metabolism[MESH]Chemical evolution for taming the pathogenic kinase PAK1 (epmc).pdf DeepDyve Pubget Overpricing